Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo. These dynamics can rattle even the most seasoned professionals, which is why we started StockStory - to help you separate the good companies from the bad. That said, here are three mid-cap stocks to swipe left on and some alternatives you should look into instead. Genuine Parts (GPC) Market Cap: $16.12 billion Largely targeting the professional customer, Genuine Parts (NYSE:GPC) sells auto and industrial parts such as batteries, belts, bearings, and machine fluids. Why Is GPC Not Exciting? Annual sales growth of 4.2% over the last six years lagged behind its consumer retail peers as its large revenue base made it difficult to generate incremental demand Weak same-store sales trends over the past two years suggest there may be few opportunities in its core markets to open new locations Day-to-day expenses have swelled relative to revenue over the last year as its operating margin fell by 2.1 percentage points At $115.19 per share, Genuine Parts trades at 14.1x forward price-to-earnings. Read our free research report to see why you should think twice about including GPC in your portfolio, it’s free. Jabil (JBL) Market Cap: $14.87 billion With manufacturing facilities spanning the globe from China to Mexico to the United States, Jabil (NYSE:JBL) provides electronics design, manufacturing, and supply chain solutions to companies across various industries, from healthcare to automotive to cloud computing. Why Do We Think Twice About JBL? Customers postponed purchases of its products and services this cycle as its revenue declined by 11.6% annually over the last two years Flat earnings per share over the last two years lagged its peers Low free cash flow margin of 3.1% for the last five years gives it little breathing room, constraining its ability to self-fund growth or return capital to shareholders Jabil’s stock price of $138.21 implies a valuation ratio of 14.5x forward price-to-earnings. Dive into our free research report to see why there are better opportunities than JBL. Royalty Pharma (RPRX) Market Cap: $13.73 billion Pioneering a unique business model in the pharmaceutical industry since 1996, Royalty Pharma (NASDAQ:RPRX) acquires rights to receive portions of sales from successful biopharmaceutical products, providing funding to drug developers without conducting research itself. Story Continues Why Does RPRX Worry Us? Flat sales over the last two years suggest it must find different ways to grow during this cycle Subscale operations are evident in its revenue base of $2.26 billion, meaning it has fewer distribution channels than its larger rivals Efficiency has decreased over the last five years as its adjusted operating margin fell by 18.1 percentage points Royalty Pharma is trading at $32.49 per share, or 6.5x forward price-to-earnings. To fully understand why you should be careful with RPRX, check out our full research report (it’s free). Stocks We Like More The market surged in 2024 and reached record highs after Donald Trump’s presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we’re homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver’s seat and build a durable portfolio by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years. Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Sterling Infrastructure (+1,096% five-year return). Find your next big winner with StockStory today for free. View Comments
3 Mid-Cap Stocks Facing Headwinds
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...